Breaking News Instant updates and real-time market news.

APLS

Apellis

$29.13

-0.47 (-1.59%)

08:03
09/03/19
09/03
08:03
09/03/19
08:03

Apellis doses first patient in Phase 3 study of APL-2

Apellis Pharmaceuticals announced the dosing of the first patient in the Phase 3 clinical study PRINCE, evaluating the efficacy and safety of APL-2 for treatment-naive patients with paroxysmal nocturnal hemoglobinuria. PRINCE is the second Phase 3 study that Apellis has initiated to investigate the potential of APL-2 to treat PNH. The PRINCE study is a Phase 3, randomized, multicenter, open-label, controlled study that aims to enroll 54 treatment-naive adult patients with PNH. The primary objective of this study is to evaluate the efficacy of APL-2 in patients with PNH who are currently not being treated with complement inhibitors, as assessed by hemoglobin stabilization from baseline in the absence of transfusion through Week 26 and reduction in lactate dehydrogenase level from baseline to Week 26.

  • 04

    Sep

  • 04

    Sep

  • 09

    Sep

  • 09

    Sep

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

APLS Apellis
$29.13

-0.47 (-1.59%)

07/08/19
OPCO
07/08/19
INITIATION
Target $52
OPCO
Outperform
Apellis initiated with an Outperform at Oppenheimer
Oppenheimer analyst Justin Kim initiated Apellis with an Outperform rating and $52 price target.
07/09/19
07/09/19
INITIATION
Target $52

Outperform
Oppenheimer bullish on Apellis, initiates with an Outperform
As previously reported, Oppenheimer analyst Justin Kim started coverage of Apellis with an Outperform rating and $52 price target. The analyst believes its lead asset APL-2 is well positioned to address the high unmet need in geographic atrophy where no treatment options currently exist, while also addressing deeper unmet need in a defined orphan blood disorder. With the Phase 3 PNH study fully enrolled and Phase 3 studies in GA enrolling this year, Kim anticipates the shares could re-rate favorably over the coming 12-18 months.
07/12/19
JPMS
07/12/19
UPGRADE
Target $49
JPMS
Overweight
Apellis upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Apellis Pharmaceuticals to Overweight from Neutral and raised his price target for the shares to $49 from $35.
07/12/19
JPMS
07/12/19
UPGRADE
Target $49
JPMS
Overweight
Apellis upgraded to Overweight with $49 price target at JPMorgan
JPMorgan analyst Anupam Rama upgraded Apellis Pharmaceuticals to Overweight from Neutral and raised his price target for the shares to $49 from $35.The analyst continues to believe APL-2 is an underappreciated asset in the complement space, with opportunities that span geographic atrophy and paroxysmal nocturnal hemoglobinuria in the later stage. Investor focus in the near term will be on the upcoming phase 3 PEGASUS readout of APL-2 in PNH anticipated in December, Rama tells investors in a research note. Early data with APL-2 suggests a potential differentiated option in the disease with respect to hemoglobin increase and other hematological indicators, he adds.

TODAY'S FREE FLY STORIES

SAM

Boston Beer

$345.20

-6.42 (-1.83%)

09:03
09/23/19
09/23
09:03
09/23/19
09:03
Hot Stocks
Boston Beer, National Hockey League announce multiyear U.S. partnership »

The Boston Beer Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

LYFT

Lyft

$46.45

-0.84 (-1.78%)

, UBER

Uber

$32.52

-1.31 (-3.87%)

09:03
09/23/19
09/23
09:03
09/23/19
09:03
Recommendations
Lyft, Uber analyst commentary  »

Lyft should be bought on…

LYFT

Lyft

$46.45

-0.84 (-1.78%)

UBER

Uber

$32.52

-1.31 (-3.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SDXAY

Sodexo

$0.00

(0.00%)

09:03
09/23/19
09/23
09:03
09/23/19
09:03
Hot Stocks
Sodexo confirms 34% carbon emissions reduction target by 2025 »

Sodexo confirmed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:01
09/23/19
09/23
09:01
09/23/19
09:01
Conference/Events
UBS to hold a conference »

Future of Retail…

AJG

Arthur J. Gallagher

$88.78

-0.64 (-0.72%)

09:01
09/23/19
09/23
09:01
09/23/19
09:01
Hot Stocks
Arthur J. Gallagher acquires The Human Capital Group, terms not disclosed »

Arthur J. Gallagher &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$172.68

-4.23 (-2.39%)

09:01
09/23/19
09/23
09:01
09/23/19
09:01
Recommendations
Nvidia analyst commentary  »

Nvidia price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$2.46

0.01 (0.41%)

, CHWY

Chewy

$26.44

-1.06 (-3.85%)

08:59
09/23/19
09/23
08:59
09/23/19
08:59
Hot Stocks
Fly Intel: Pre-market Movers »

HIGHER: Plus Therapeutics…

MNK

Mallinckrodt

$2.46

0.01 (0.41%)

CHWY

Chewy

$26.44

-1.06 (-3.85%)

ALV

Autoliv

$78.20

-1.06 (-1.34%)

PSTV

Plus Therapeutics

$7.96

-0.34 (-4.10%)

TELL

Tellurian

$8.69

0.105 (1.22%)

RKDA

Arcadia Biosciences

$5.29

-0.23 (-4.17%)

CLF

Cleveland-Cliffs

$7.73

-0.235 (-2.95%)

X

U.S. Steel

$10.81

-0.25 (-2.26%)

AKS

AK Steel

$2.41

-0.05 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

  • 31

    Oct

ABMD

Abiomed

$193.14

0.48 (0.25%)

08:59
09/23/19
09/23
08:59
09/23/19
08:59
Hot Stocks
Federal Court of Justice in Germany rules in favor of Abiomed's Impella patents »

The highest court in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

MU

Micron

$49.17

-0.65 (-1.30%)

08:58
09/23/19
09/23
08:58
09/23/19
08:58
Recommendations
Micron analyst commentary  »

Deutsche comfortable with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

CRUS

Cirrus Logic

$54.36

-0.59 (-1.07%)

, NXPI

NXP Semiconductors

$104.69

-3.74 (-3.45%)

08:55
09/23/19
09/23
08:55
09/23/19
08:55
Recommendations
Cirrus Logic, NXP Semiconductors, Texas Instruments analyst commentary  »

Teardown confirms Cirrus…

CRUS

Cirrus Logic

$54.36

-0.59 (-1.07%)

NXPI

NXP Semiconductors

$104.69

-3.74 (-3.45%)

TXN

Texas Instruments

$126.70

-2.1 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

NFLX

Netflix

$270.66

-15.92 (-5.56%)

, ROKU

Roku

$107.98

-25.735 (-19.25%)

08:55
09/23/19
09/23
08:55
09/23/19
08:55
Options
Notable open interest changes for September 23rd »

Friday's total…

NFLX

Netflix

$270.66

-15.92 (-5.56%)

ROKU

Roku

$107.98

-25.735 (-19.25%)

BAC

Bank of America

$29.57

-0.23 (-0.77%)

AAPL

Apple

$217.69

-3.22 (-1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Sep

  • 16

    Oct

  • 16

    Oct

SABR

Sabre

$23.11

0.12 (0.52%)

08:54
09/23/19
09/23
08:54
09/23/19
08:54
Hot Stocks
Sabre signs long-term agreement with Magnum Travel Services »

Sabre announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DG

Dollar General

$156.29

-0.66 (-0.42%)

08:53
09/23/19
09/23
08:53
09/23/19
08:53
Recommendations
Dollar General analyst commentary  »

Dollar General price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 30

    Sep

CLF

Cleveland-Cliffs

$7.73

-0.235 (-2.95%)

08:51
09/23/19
09/23
08:51
09/23/19
08:51
Downgrade
Cleveland-Cliffs rating change  »

JPMorgan downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

INPX

Inpixon

$0.13

0.0013 (0.98%)

08:50
09/23/19
09/23
08:50
09/23/19
08:50
Hot Stocks
Inpixon's Jibestream signs teaming agreement with IDENTOS »

Jibestream announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:50
09/23/19
09/23
08:50
09/23/19
08:50
General news
NY Fed's repo results: Fed's repo totaled $65.75 B »

NY Fed's repo…

CGNX

Cognex

$48.20

-2.28 (-4.52%)

08:48
09/23/19
09/23
08:48
09/23/19
08:48
Recommendations
Cognex analyst commentary  »

Cognex price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AA

Alcoa

$21.70

-0.26 (-1.18%)

, X

U.S. Steel

$10.81

-0.25 (-2.26%)

08:48
09/23/19
09/23
08:48
09/23/19
08:48
Downgrade
Alcoa, U.S. Steel, Commercial Metals, Nucor, Steel Dynamics, Stelco Holdings rating change  »

JPMorgan double…

AA

Alcoa

$21.70

-0.26 (-1.18%)

X

U.S. Steel

$10.81

-0.25 (-2.26%)

CMC

Commercial Metals

$17.94

-0.42 (-2.29%)

NUE

Nucor

$52.62

-0.08 (-0.15%)

STLD

Steel Dynamics

$30.38

-0.32 (-1.04%)

STZHF

Stelco Holdings

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 16

    Oct

ABEO

Abeona Therapeutics

$3.26

-0.005 (-0.15%)

08:48
09/23/19
09/23
08:48
09/23/19
08:48
Hot Stocks
Abeona recieves clinical hold letter from FDA over Phase 3 trial for EB-101 »

Abeona Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

FNB

F.N.B.

$11.38

-0.045 (-0.39%)

08:47
09/23/19
09/23
08:47
09/23/19
08:47
Hot Stocks
F.N.B. announces $150M stock repurchase program »

F.N.B. announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

08:47
09/23/19
09/23
08:47
09/23/19
08:47
Hot Stocks
Resverlogix to present BETonMACE trial results at AHA Scientific Sessions »

Resverlogix announced the…

PRSP

Perspecta

$26.29

-0.005 (-0.02%)

08:46
09/23/19
09/23
08:46
09/23/19
08:46
Hot Stocks
Perspecta awarded $657M extension of NGEN contract with U.S. Dept. of Navy »

Perspecta announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.69

-3.22 (-1.46%)

08:45
09/23/19
09/23
08:45
09/23/19
08:45
Hot Stocks
Apple partners with Oprah Winfrey to bring Oprah's Book Club to Apple »

Apple and Oprah Winfrey…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BYND

Beyond Meat

$155.23

0.19 (0.12%)

, HEXO

HEXO Corp

$4.37

0.425 (10.79%)

08:45
09/23/19
09/23
08:45
09/23/19
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

BYND

Beyond Meat

$155.23

0.19 (0.12%)

HEXO

HEXO Corp

$4.37

0.425 (10.79%)

FCAU

Fiat Chrysler

$13.52

-0.11 (-0.81%)

ABBV

AbbVie

$72.46

0.78 (1.09%)

QSR

Restaurant Brands

$72.64

-1.24 (-1.68%)

COTY

Coty

$10.17

-0.1 (-0.97%)

ADI

Analog Devices

$115.30

-0.72 (-0.62%)

NOK

Nokia

$5.30

0.145 (2.81%)

IMMU

Immunomedics

$16.60

-0.44 (-2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

  • 02

    Oct

  • 12

    Nov

08:45
09/23/19
09/23
08:45
09/23/19
08:45
General news
U.S. Chicago National Activity index rose 0.51 points to 0.10 in August »

U.S. Chicago National…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.